SLPI (secretory leukocyte peptidase inhibitor)

Show simple item record Ambrosi, Nella - Guerrieri, Diego - Caro, Fiorella - Barbieri Kennedy, Micaela - Sanchez, Francisco - 2017-10-13T09:25:25Z 2017-10-13T09:25:25Z 2016 -
dc.identifier.citation Nella, Ambrosi ; Diego, Guerrieri ; Fiorella, Caro ; Micaela, Barbieri Kennedy ; Francisco, Sanchez. SLPI (secretory leukocyte peptidase inhibitor). Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2016, 6, p. 331-340 -
dc.identifier.issn 1768-3262 -
dc.description.abstract Secretory Leukocyte Peptidase Inhibitor (SLPI) functionality in health and disease: Secretory Leukocyte Peptidase Inhibitor (SLPI) is a serine protease inhibitor of cathepsin G, trypsin and chymotrypsin, but primarily against neutrophil elastase. Its major function is to inhibit inflammation by blocking the proteolytic activity of these proteinases released by leukocytes and also through down-modulation of several cytokines. The anti-inflammatory activity is also mediated by inhibition of the activation of the transcription nuclear factor NF-kB. Some studies localized the molecule within the cytosol and in secondary granules of neutrophils. Because of this, it is believed that neutrophil-derived SLPI may regulate the protease/antiprotease balance at sites of tissue inflammation. In relation with the adaptive immune system, it was suggested that SLPI modulates the cellular and humoral immune response, by decreasing the T cell proliferation and reducing the class switching. Also, it is known that this polycationic non-glycosylated peptide, displays anti-microbial properties against bacteria, viruses (in particular HIV) and fungus. In summary, the SLPI is a pleitropic molecule, implicated in physiological and pathological events, such as wound healing, pregnancy, chronic obstructive pulmonary disease, cancer, ischemia reperfusion injury and stroke, among others. Their detection in serum and biological fluids may be useful as a biomarker to diagnosis and prognosis for certain diseases. en
dc.language.iso en -
dc.publisher Jean-Loup Huret (Editor-in-Chief) -
dc.relation Atlas of Genetics and Cytogenetics in Oncology and Haematology ; -
dc.relation.ispartofseries Atlas of Genetics and Cytogenetics in Oncology and Haematology en
dc.rights Open access resource - terms and conditions : -
dc.subject SLPI en
dc.subject antimicrobial activity en
dc.subject anti-inflammatory activity en
dc.subject anti-tumoral activity en
dc.subject.classification Genes Section en
dc.subject.mesh Adult en
dc.subject.mesh Animals en
dc.subject.mesh Female en
dc.subject.mesh Humans en
dc.subject.mesh Male en
dc.subject.mesh Mice en
dc.subject.mesh Mice, Knockout en
dc.subject.mesh Neutrophils/*metabolism en
dc.subject.mesh Psoriasis/immunology en
dc.subject.mesh Secretory Leukocyte Peptidase Inhibitor/genetics/*physiology en
dc.subject.mesh Adult en
dc.subject.mesh Cervix Uteri/*immunology/metabolism/pathology en
dc.subject.mesh Elafin/biosynthesis/*immunology en
dc.subject.mesh Female en
dc.subject.mesh Gene Expression Regulation/*immunology en
dc.title SLPI (secretory leukocyte peptidase inhibitor) en
dc.type Article -
dc.contributor.affiliation CEFYBO-CONICET, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina -

Files in this item

PDF 08-2015-SLPIID46048ch20q13.pdf 191.0Kb

This item appears in the following Collection(s)

Show simple item record

Advanced Search